Today results from the first-in-human study ACP-001 was made public at the 2020 EHA meeting.
Key findings from the study:
- Overall survival (OS) 100% after a median follow-up time of 60 months
- Median progression free survival (PFS) 34 months
- No serious adverse events
The present study demonstrates that autologous NK cell-based immunotherapy is feasible and demonstrates clinical applicability with efficacy responses in an upfront autologous HSCT-setting in multiple myeloma (MM). The treatment strategy opens for usage of autologous NK cells in clinical settings where patients are not readily eligible for allogeneic NK cell-based treatments, including MRD and maintenance treatment in MM and other forms of malignancies.
